Effector T cell cytokine secretion

Effector T cell cytokine secretion refers to the physiological process by which activated T lymphocytes release signaling proteins—such as IFN-gamma, TNF-alpha, and various interleukins—to orchestrate the adaptive immune response [1]. This process is initiated following T-cell receptor (TCR) engagement with antigen-MHC complexes, which triggers downstream signaling pathways including the calcineurin-NFAT, MAPK, and NF-kappaB pathways [2]. While essential for defense against pathogens and tumors, aberrant or chronic cytokine secretion is a primary driver of tissue damage in autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease [3]. In the context of drug discovery, this process is frequently used as a phenotypic endpoint in functional assays to evaluate the potency of immunosuppressive or immunostimulatory agents [4]. Because it encompasses a broad cascade of molecular interactions involving multiple receptors, kinases, and transcription factors, it is characterized as a biological pathway or cellular process rather than a single druggable molecular target [5].

Other names

T-cell cytokine productionEffector T-lymphocyte cytokine releaseTh1/Th2/Th17 cytokine secretionT-cell effector function

Modulation of T-cell cytokine secretion is achieved through several mechanisms: inhibition of calcineurin (preventing NFAT translocation), blockade of co-stimulatory signals (CD28-B7 interaction), inhibition of Janus kinases (JAK-STAT pathway), or direct neutralization of secreted cytokines using monoclonal antibodies.